Plumbagin (Synonyms: 2-Methyljuglone)

Name: Plumbagin
Brand: MedChemExpress
SKU: HY-N1497
Rating: 5.0 (3 reviews)

Cat. No.: HY-N1497 Purity: 99.74%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Plumbagin (2-Methyljuglone) is a naphthoquinone isolated from Plumbago zeylanica, exhibits anticancer and antiproliferative activities.

For research use only. We do not sell to patients.

CAS No. : 481-42-5

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Plumbagin:

Plumbagin (Standard) Get quote

3 Publications Citing Use of MCE Plumbagin

Cell Proliferation/Viability Assay

Apoptosis Analysis

RT-PCR

Histological Imaging/Staining

: Plumbagin purchased from MedChemExpress. Usage Cited in: Crit Rev Eukaryot Gene Expr. 2025;35(2):13-25.; Effect of indicated Plumbagin (PL) concentration gradients on proliferation of SU-DHL-4 cells in 12, 24, and 36 hours.

: Plumbagin purchased from MedChemExpress. Usage Cited in: Crit Rev Eukaryot Gene Expr. 2025;35(2):13-25.; Flow cytometry analysis of SU-DHL-4 cell apoptosis after stimulation with control: 1.0 and 1.5 μM Plumbagin (PL) for 24 hours.

: Plumbagin purchased from MedChemExpress. Usage Cited in: Crit Rev Eukaryot Gene Expr. 2025;35(2):13-25.; Western blot analysis and quantification of caspase 3, Bcl 2, Bax protein expression in control, and 1.0 and 1.5 μM Plumbagin (PL) treated SU-DHL-4 cells after 24 hours.

: Plumbagin purchased from MedChemExpress. Usage Cited in: Crit Rev Eukaryot Gene Expr. 2025;35(2):13-25.; mRNA expression of catalase, SOD1, and SOD2 as determined by QPCR treated with 1.0 and 1.5 μM Plumbagin (PL).

: Plumbagin purchased from MedChemExpress. Usage Cited in: Crit Rev Eukaryot Gene Expr. 2025;35(2):13-25.; HE staining in tumor tissues of control and Plumbagin (PL) (2 mg/kg, i.p.)-treated DLBCL-xenograft mice.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Plumbagin (2-Methyljuglone) is a naphthoquinone isolated from Plumbago zeylanica, exhibits anticancer and antiproliferative activities^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	12.4 μM Compound: 1; PL	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 28558333]
A549	IC₅₀	3 μM Compound: 2	Growth inhibition of human A549 cells by MTT assay Growth inhibition of human A549 cells by MTT assay	[PMID: 26706169]
A549	IC₅₀	7.2 μM Compound: 2	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
A549	IC₅₀	8.9 μM Compound: PL ; 1	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 29772386]
ACHN	EC₅₀	3.7 μM Compound: 6	Cytotoxicity against human ACHN cells assessed as cell death after 20 to 24 hrs by XTT assay Cytotoxicity against human ACHN cells assessed as cell death after 20 to 24 hrs by XTT assay	[PMID: 22313254]
ACHN	EC₅₀	7.3 μM Compound: 6	Cytotoxicity against human ACHN cells assessed as cell death after 20 to 24 hrs by XTT assay in presence of 40 ng/ml TRAIL Cytotoxicity against human ACHN cells assessed as cell death after 20 to 24 hrs by XTT assay in presence of 40 ng/ml TRAIL	[PMID: 22313254]
B16-F10	IC₅₀	1 μM Compound: 2	Growth inhibition of mouse B16F10 cells by MTT assay Growth inhibition of mouse B16F10 cells by MTT assay	[PMID: 26706169]
BT-474	IC₅₀	0.8 μM Compound: 1, Plumbagin	Cytotoxicity against Her2-overexpressing human BT474 cells after 72 hrs by MTT assay Cytotoxicity against Her2-overexpressing human BT474 cells after 72 hrs by MTT assay	[PMID: 22512718]
BT-474	IC₅₀	1.8 μM Compound: 1, Plumbagin	Cytotoxicity against Her2-overexpressing human BT474 cells after 24 hrs by MTT assay Cytotoxicity against Her2-overexpressing human BT474 cells after 24 hrs by MTT assay	[PMID: 22512718]
DU-145	IC₅₀	5.23 μM Compound: Plumbagin	Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23791367]
HCT-116	IC₅₀	20 μM Compound: 1	Cytotoxicity against human HCT116 cells expressing p53 assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells expressing p53 assessed as cell viability after 24 hrs by MTT assay	[PMID: 24828199]
HCT-116	IC₅₀	20 μM Compound: 1	Cytotoxicity against p53-deficient human HCT116 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against p53-deficient human HCT116 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24828199]
HCT-116	IC₅₀	9.8 μM Compound: PL ; 1	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 29772386]
HEK293	EC₅₀	0.46 μM Compound: 7	Activation of human TRPA1 expressed in HEK293 cells assessed as increase in calcium level by fluo-4 dye based plate reader analysis Activation of human TRPA1 expressed in HEK293 cells assessed as increase in calcium level by fluo-4 dye based plate reader analysis	[PMID: 26905390]
HK-2	IC₅₀	23.58 μM Compound: PL ; 1	Cytotoxicity against human HK2 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HK2 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 29772386]
HL-60	IC₅₀	1.1 μM Compound: 2	Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
HL-60	IC₅₀	1.5 μM Compound: Plumbagin	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 48 to 72 hrs by MTT assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 48 to 72 hrs by MTT assay	[PMID: 38458106]
HL-60	IC₅₀	3.67 μM Compound: Plumbagin	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 30007564]
HL-60	IC₅₀	8.25 μM Compound: Plumbagin	Cytotoxicity against human HL60 cells after 24 hrs by MTT assay Cytotoxicity against human HL60 cells after 24 hrs by MTT assay	[PMID: 30007564]
HT-29	IC₅₀	26.2 μM Compound: 1b	Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
HT-29	IC₅₀	26.2 μM Compound: 47	Antitumor activity against human HT-29 cells assessed as cell growth inhibition Antitumor activity against human HT-29 cells assessed as cell growth inhibition	[PMID: 36858050]
HT-29	IC₅₀	4.19 μM Compound: Plumbagin	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23791367]
HUVEC	ED₅₀	0.4 μg/mL Compound: 1	Cytotoxicity against human HUVEC Cytotoxicity against human HUVEC	[PMID: 15270571]
HeLa	IC₅₀	10.2 μM Compound: Plumbagin	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 33766765]
HeLa	IC₅₀	20 μM Compound: 18a	Inhibition of P300 in human HeLa cells using [3H]-acetyl-CoA as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by liquid scintillation counting analysis Inhibition of P300 in human HeLa cells using [3H]-acetyl-CoA as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by liquid scintillation counting analysis	[PMID: 31195169]
HeLa	IC₅₀	25.5 μM Compound: 1a	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 24913712]
HeLa	IC₅₀	59 μM Compound: 1b	Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
HeLa	IC₅₀	59 μM Compound: 47	Antitumor activity against human HeLa cells assessed as cell growth inhibition Antitumor activity against human HeLa cells assessed as cell growth inhibition	[PMID: 36858050]
HeLa	IC₅₀	> 50 μM Compound: 18a	Inhibition of PCAF in human HeLa cells using [3H]-acetyl-CoA as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by liquid scintillation counting analysis Inhibition of PCAF in human HeLa cells using [3H]-acetyl-CoA as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by liquid scintillation counting analysis	[PMID: 31195169]
HepG2	IC₅₀	10.66 μM Compound: 1; PL	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 28558333]
HepG2	IC₅₀	9.17 μM Compound: PL ; 1	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 29772386]
Hs 683	IC₅₀	4 μM Compound: 2	Growth inhibition of human Hs683 cells by MTT assay Growth inhibition of human Hs683 cells by MTT assay	[PMID: 26706169]
Jurkat	IC₅₀	0.95 μM Compound: 2	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
KB	ED₅₀	0.3 μg/mL Compound: 1	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 15270571]
KB	IC₅₀	9.83 μM Compound: Plumbagin	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 33766765]
LNCaP	ED₅₀	0.4 μg/mL Compound: 1	Cytotoxicity against human LNCAP cells Cytotoxicity against human LNCAP cells	[PMID: 15270571]
LS174T	IC₅₀	9.9 μM Compound: 2	Cytotoxicity against human LS174T cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human LS174T cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
Lu1	ED₅₀	0.3 μg/mL Compound: 1	Cytotoxicity against human Lu1 cells Cytotoxicity against human Lu1 cells	[PMID: 15270571]
MCF7	IC₅₀	1 μM Compound: Plumbagin	Cytotoxicity against human MCF7 cells incubated for 7 days by MTT assay Cytotoxicity against human MCF7 cells incubated for 7 days by MTT assay	[PMID: 38458106]
MCF7	IC₅₀	1.5 μM Compound: Plumbagin	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based ELISA Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based ELISA	[PMID: 38458106]
MCF7	IC₅₀	12.2 μM Compound: 1b	Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
MCF7	IC₅₀	12.2 μM Compound: 47	Antitumor activity against human MCF7 cells assessed as cell growth inhibition Antitumor activity against human MCF7 cells assessed as cell growth inhibition	[PMID: 36858050]
MCF7	IC₅₀	2.84 μM Compound: 13	Cytotoxicity against human MCF7 cells expressing HER2 assessed as reduction of cell viability after 48 hrs CellTiter-Glo assay Cytotoxicity against human MCF7 cells expressing HER2 assessed as reduction of cell viability after 48 hrs CellTiter-Glo assay	[PMID: 24355130]
MCF7	IC₅₀	3 μM Compound: 2	Growth inhibition of human MCF7 cells by MTT assay Growth inhibition of human MCF7 cells by MTT assay	[PMID: 26706169]
MCF7	IC₅₀	3.35 μM Compound: 13	Cytotoxicity against human MCF7 cells expressing pcDNA3 assessed as reduction of cell viability after 48 hrs CellTiter-Glo assay Cytotoxicity against human MCF7 cells expressing pcDNA3 assessed as reduction of cell viability after 48 hrs CellTiter-Glo assay	[PMID: 24355130]
MCF7	IC₅₀	3.5 μM Compound: Plumbagin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 30810041]
MCF7	IC₅₀	3.5 μM Compound: Plumbagin	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 33234343]
MCF7	IC₅₀	3.5 μM Compound: Plumbagin	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 36846377]
MCF7	IC₅₀	4.1 μM Compound: 2	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
MCF7	IC₅₀	5.1 μM Compound: 13	Cytotoxicity against human MCF7 cells expressing HER2delta16 assessed as reduction of cell viability after 48 hrs CellTiter-Glo assay Cytotoxicity against human MCF7 cells expressing HER2delta16 assessed as reduction of cell viability after 48 hrs CellTiter-Glo assay	[PMID: 24355130]
MCF7	IC₅₀	5.5 μM Compound: 1	Antiproliferative activity against ER-positive human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against ER-positive human MCF7 cells after 24 hrs by MTT assay	[PMID: 22483392]
MCF7/PTX	IC₅₀	3.5 μM Compound: Plumbagin	Cytotoxicity against paclitaxel-resistant human MCF7/PTX cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against paclitaxel-resistant human MCF7/PTX cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 30810041]
MDA-MB-231	IC₅₀	1.5 μM Compound: Plumbagin	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based ELISA Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based ELISA	[PMID: 38458106]
MDA-MB-231	IC₅₀	14.23 μM Compound: 1; PL	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 28558333]
MDA-MB-231	IC₅₀	21.24 μM Compound: Plumbagin	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23791367]
MDA-MB-231	IC₅₀	3.5 μM Compound: 1	Antiproliferative activity against ER-negative human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against ER-negative human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 22483392]
MDA-MB-231	IC₅₀	4.4 μM Compound: Plumbagin	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 33234343]
MDA-MB-231	IC₅₀	51.1 μM Compound: 47	Antitumor activity against human MDA-MB-231 cells assessed as cell growth inhibition Antitumor activity against human MDA-MB-231 cells assessed as cell growth inhibition	[PMID: 36858050]
MDA-MB-231	IC₅₀	51.12 μM Compound: 1b	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
MDA-MB-231	IC₅₀	6.5 μM Compound: PL ; 1	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 29772386]
MDA-MB-453	IC₅₀	34.5 μM Compound: 47	Antitumor activity against human MDA-MB-453 cells assessed as cell growth inhibition Antitumor activity against human MDA-MB-453 cells assessed as cell growth inhibition	[PMID: 36858050]
MDA-MB-453	IC₅₀	34.56 μM Compound: 1b	Cytotoxicity against human MDA-MB-453 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-453 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
MDA-MB-468	IC₅₀	2.5 μM Compound: 1	Antiproliferative activity against ER-negative human MDA-MB-468 cells after 48 hrs by MTT assay Antiproliferative activity against ER-negative human MDA-MB-468 cells after 48 hrs by MTT assay	[PMID: 22483392]
ME-180	IC₅₀	43.4 μM Compound: 1b	Cytotoxicity against human ME180 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human ME180 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
ME-180	IC₅₀	43.4 μM Compound: 47	Antitumor activity against human ME-180 cells assessed as cell growth inhibition Antitumor activity against human ME-180 cells assessed as cell growth inhibition	[PMID: 36858050]
MONO-MAC-6	IC₅₀	2.6 μM Compound: 2	Cytotoxicity against human MONO-MAC-6 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human MONO-MAC-6 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
PANC-1	IC₅₀	23.7 μM Compound: 1	Cytotoxicity against human PANC-1 cells in Dulbecco's modified Eagle's medium assessed as reduction in cell viability incubated for 24 hrs by WST-8 cell counting analysis Cytotoxicity against human PANC-1 cells in Dulbecco's modified Eagle's medium assessed as reduction in cell viability incubated for 24 hrs by WST-8 cell counting analysis	[PMID: 37257133]
PBMC	EC₅₀	0.8 μM Compound: 1	Cytotoxicity against human PBMC cells assessed as viable fractions using annexin V-FITC/propidium iodide staining by flow cytometry Cytotoxicity against human PBMC cells assessed as viable fractions using annexin V-FITC/propidium iodide staining by flow cytometry	[PMID: 22019229]
PBMC	IC₅₀	2.7 μM Compound: 2	Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
PC-3	IC₅₀	17.19 μM Compound: 1b	Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
PC-3	IC₅₀	17.2 μM Compound: 47	Antitumor activity against human PC-3 cells assessed as cell growth inhibition Antitumor activity against human PC-3 cells assessed as cell growth inhibition	[PMID: 36858050]
SAS	IC₅₀	3 μM Compound: 1a	Cytotoxicity against human SAS cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human SAS cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 24913712]
SK-BR-3	IC₅₀	1.8 μM Compound: 1, Plumbagin	Cytotoxicity against Her2-overexpressing human SKBR3 cells after 72 hrs by MTT assay Cytotoxicity against Her2-overexpressing human SKBR3 cells after 72 hrs by MTT assay	[PMID: 22512718]
SK-BR-3	IC₅₀	3.2 μM Compound: 1, Plumbagin	Cytotoxicity against Her2-overexpressing human SKBR3 cells after 24 hrs by MTT assay Cytotoxicity against Her2-overexpressing human SKBR3 cells after 24 hrs by MTT assay	[PMID: 22512718]
SK-MEL-28	IC₅₀	5 μM Compound: 2	Growth inhibition of human SK-MEL-28 cells by MTT assay Growth inhibition of human SK-MEL-28 cells by MTT assay	[PMID: 26706169]
SMMC-7721	IC₅₀	2.43 μM Compound: 10	Antitumor activity against human SMMC-7721 cells measured after 24 hrs Antitumor activity against human SMMC-7721 cells measured after 24 hrs	[PMID: 34669417]
SMMC-7721	IC₅₀	36.05 μM Compound: 10	Antitumor activity against human SMMC-7721 cells measured after 6 hrs Antitumor activity against human SMMC-7721 cells measured after 6 hrs	[PMID: 34669417]
SMMC-7721	IC₅₀	5.41 μM Compound: 10	Antitumor activity against human SMMC-7721 cells measured after 12 hrs Antitumor activity against human SMMC-7721 cells measured after 12 hrs	[PMID: 34669417]
SW-620	IC₅₀	7.4 μM Compound: 1	Cytotoxicity against human SW620 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human SW620 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 24828199]
SW-620	IC₅₀	7.7 μM Compound: 1	Cytotoxicity against human SW620 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human SW620 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24828199]
SW480	IC₅₀	12 μM Compound: 1	Cytotoxicity against human SW480 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24828199]
SW480	IC₅₀	7.3 μM Compound: 1	Cytotoxicity against human SW480 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 24828199]
SW982	IC₅₀	3.6 μM Compound: 2	Cytotoxicity against human SW982 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human SW982 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
Sf21	IC₅₀	2 μM Compound: 99	Inhibition of recombinant full length p300 (unknown origin) expressed in baculovirus infected insect Sf21 cells using [3H]acetyl-CoA as substrate Inhibition of recombinant full length p300 (unknown origin) expressed in baculovirus infected insect Sf21 cells using [3H]acetyl-CoA as substrate	10.1039/C1MD00199J
Sf9	IC₅₀	> 100 μM Compound: 4, ZINC-58187	Inhibition of human recombinant GST-fused NIK expressed in Sf9 cells after 60 mins by radiometric protein kinase assay Inhibition of human recombinant GST-fused NIK expressed in Sf9 cells after 60 mins by radiometric protein kinase assay	[PMID: 20580552]
THP-1	IC₅₀	1.1 μM Compound: 2	Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
U-373MG ATCC	IC₅₀	5 μM Compound: 2	Growth inhibition of human U373 cells by MTT assay Growth inhibition of human U373 cells by MTT assay	[PMID: 26706169]
U-937	IC₅₀	2.4 μM Compound: 2	Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 31563013]
WI-38	IC₅₀	26.71 μM Compound: Plumbagin	Cytotoxicity against human WI38 cells after 48 hrs by MTT assay Cytotoxicity against human WI38 cells after 48 hrs by MTT assay	[PMID: 30007564]
WRL68	IC₅₀	15.36 μM Compound: PL ; 1	Cytotoxicity against human WRL68 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human WRL68 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 29772386]

In Vitro

Plumbagin (0, 5, 10, and 15 μM) induces apoptosis of prostate cancer cell lines, such as DU145, CWR22rv1 and LNCaP, in a dose-dependent manner^[1].
Plumbagin (5, 20 μM) obviously inhibits the invasion of PC3, DU145, and CWR22rv1 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:	DU145, CWR22rv1, LNCaP and RWPE-1 cells
Concentration:	0, 5, 10, and 15 μM
Incubation Time:	24 hours
Result:	Dose-dependently induced apoptosis of DU145, CWR22rv1 and LNCaP, but showed no effect on RWPE-1 cells at up to 20 μM.

In Vivo

Plumbagin (2 mg/kg, i.p., five days a week for 11 weeks) inhibits the growth of tumor in male athymic nude mice^[1].
Plumbagin (2 mg/kg, i.p., five days a week for 11 weeks) inhibits expression of PKCε, suppresses JAK-2 and Stat3 phosphorylation, and activates Stat3, PCNA, VEGF and MMP-9 in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male athymic nude mice bearing DU145 cells^[1]
Dosage:	2 mg/kg
Administration:	I.P. after 3 days post cell implantation, five days a week.
Result:	Delayed tumor growth by 3 weeks, and reduced tumor weight and volume in mice.

Molecular Weight

188.18

Formula

C₁₁H₈O₃

CAS No.

481-42-5

Appearance

Solid

Color

Light yellow to orange

SMILES

O=C1C(C)=CC(C2=C1C=CC=C2O)=O

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : ≥ 150 mg/mL (797.11 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	5.3141 mL	26.5703 mL	53.1406 mL
5 mM	1.0628 mL	5.3141 mL	10.6281 mL
10 mM	0.5314 mL	2.6570 mL	5.3141 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (11.05 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (11.05 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.74%

Select Batch:

Data Sheet (279 KB) SDS (480 KB)

COA (254 KB) HNMR (228 KB) LCMS (94 KB)

Handling Instructions (2659 KB)

References

[1]. Aziz MH, et al. Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. Cancer Res. 2008 Nov 1;68(21):9024-32. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	5.3141 mL	26.5703 mL	53.1406 mL	132.8515 mL
	5 mM	1.0628 mL	5.3141 mL	10.6281 mL	26.5703 mL
	10 mM	0.5314 mL	2.6570 mL	5.3141 mL	13.2852 mL
	15 mM	0.3543 mL	1.7714 mL	3.5427 mL	8.8568 mL
	20 mM	0.2657 mL	1.3285 mL	2.6570 mL	6.6426 mL
	25 mM	0.2126 mL	1.0628 mL	2.1256 mL	5.3141 mL
	30 mM	0.1771 mL	0.8857 mL	1.7714 mL	4.4284 mL
	40 mM	0.1329 mL	0.6643 mL	1.3285 mL	3.3213 mL
	50 mM	0.1063 mL	0.5314 mL	1.0628 mL	2.6570 mL
	60 mM	0.0886 mL	0.4428 mL	0.8857 mL	2.2142 mL
	80 mM	0.0664 mL	0.3321 mL	0.6643 mL	1.6606 mL
	100 mM	0.0531 mL	0.2657 mL	0.5314 mL	1.3285 mL

Plumbagin Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Plumbagin481-42-52-MethyljugloneOthersInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Plumbagin (Synonyms: 2-Methyljuglone)

Customer Review

Other Forms of Plumbagin:

Plumbagin Related Antibodies

3 Publications Citing Use of MCE Plumbagin

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Plumbagin Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Plumbagin Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report